Do GLP-1 Agonists Lower Blood Pressure?
GLP-1 Cardiovascular
-4.95 mmHg SBP
An individual patient data meta-analysis of three RCTs found semaglutide reduced systolic blood pressure by 4.95 mmHg versus placebo, with weight loss accounting for approximately 89% of the effect.
Kennedy et al., European Heart Journal, 2024
Kennedy et al., European Heart Journal, 2024
View as imageGLP-1 receptor agonists lower blood pressure. The magnitude is modest, typically 2 to 5 mmHg systolic, but it is consistent across drugs, populations, and trial designs. A 2024 individual patient data meta-analysis by Kennedy et al. quantified the effect of semaglutide specifically at -4.95 mmHg systolic versus placebo across 3,136 participants from three randomized controlled trials.[1] That is roughly half the reduction produced by a standard antihypertensive medication, but it occurs on top of whatever blood pressure drugs a patient is already taking. For a broader view of how this fits into cardiovascular protection, see our pillar article on GLP-1 drugs and heart disease.
Key Takeaways
- Semaglutide reduced systolic blood pressure by 4.95 mmHg versus placebo in an individual patient data meta-analysis of 3,136 participants (Kennedy et al., 2024)
- A 2025 meta-analysis of 24 RCTs in overweight/obese patients found GLP-1 RAs reduced SBP by 3.37 mmHg and DBP by 1.05 mmHg (Wong et al., 2025)
- Weight loss accounts for approximately 89% of semaglutide's blood pressure reduction, with the remaining 11% attributed to weight-independent mechanisms like natriuresis
- The SURMOUNT-1 stratified analysis showed tirzepatide reduced SBP by up to 7.4 mmHg at the highest dose, with greater reductions in participants with baseline hypertension
- GLP-1 agonists increase resting heart rate by 2-4 beats per minute, partially offsetting the hemodynamic benefit of blood pressure reduction
- In the STEP obesity trials without diabetes, semaglutide reduced SBP by 4-9 mmHg, larger reductions than observed in diabetes-focused CVOTs
How large is the blood pressure reduction?
The answer depends on which drug, which population, and how you measure it.
Meta-analyses of the full GLP-1 class show systolic blood pressure reductions between 1.84 and 4.60 mmHg versus comparators. Sun et al. (2015) conducted a network meta-analysis of 60 randomized trials comparing GLP-1 receptor agonists to placebo, insulin, and sulfonylureas, finding SBP reductions ranging from -1.84 to -4.60 mmHg depending on the specific comparator.[2] Rivera et al. (2024) meta-analyzed 45 trials and reported a pooled SBP reduction of -2.39 mmHg (95% CI -3.35 to -1.44) across patients with and without diabetes.[3]
Semaglutide specifically produces somewhat larger reductions. Ala et al. (2025) systematically reviewed 20 clinical trials with over 33,000 participants and found subcutaneous semaglutide decreased SBP by 3.71 mmHg (95% CI -4.64 to -2.79) and DBP by 1.10 mmHg.[4] The Kennedy et al. individual patient data analysis found a larger effect of -4.95 mmHg, likely because individual patient data allows for more precise adjustment of confounders than aggregate meta-analyses.[1]
Tirzepatide showed even larger reductions. Krumholz et al. (2024) published a stratified analysis of the SURMOUNT-1 trial and reported SBP reductions of 5.6, 6.0, and 7.4 mmHg at the 5 mg, 10 mg, and 15 mg doses, respectively. The effect was more pronounced in participants with baseline hypertension, where reductions exceeded 8 mmHg at the highest dose.[5] Tirzepatide is a dual GLP-1/GIP receptor agonist, and whether the GIP component contributes independently to the blood pressure effect is not established.
In the CVOT context, the reductions are smaller. LEADER reported liraglutide lowered SBP by a mean of 1.2 mmHg versus placebo over 3.8 years.[6] SUSTAIN-6 showed semaglutide reduced SBP by 2.6 mmHg.[7] These smaller numbers partly reflect the fact that CVOT populations were already on antihypertensive medications and had lower baseline blood pressures. The SELECT trial enrolled patients with obesity and cardiovascular disease and found more substantial BP effects consistent with the higher doses used.
For comparison, standard antihypertensive drugs (ACE inhibitors, thiazide diuretics, calcium channel blockers) typically reduce SBP by 7 to 11 mmHg at full dose. GLP-1 agonists provide roughly one-third to one-half of that reduction.
What the obesity trials revealed about blood pressure
The largest blood pressure effects emerged in obesity trials where participants were not selected for diabetes.
In the STEP clinical program, semaglutide 2.4 mg consistently reduced blood pressure across trials. SBP reductions ranged from 4 to 9 mmHg and DBP reductions from 2 to 6 mmHg, substantially larger than what the diabetes-focused CVOTs reported.[1] The SURMOUNT-1 trial with tirzepatide reported mean SBP reductions of 6.4 mmHg and DBP reductions of 3.6 mmHg at the highest dose.[5]
The Wong et al. (2025) meta-analysis focused exclusively on overweight or obese participants across 24 randomized controlled trials, finding SBP reduced by 3.37 mmHg (95% CI -4.11 to -2.62) and DBP by 1.05 mmHg (95% CI -1.66 to -0.44). The blood pressure effects were consistent regardless of diabetes status, treatment duration, or route of administration (subcutaneous versus oral).[8]
Why are the obesity trial reductions larger? Several factors contribute. Participants in obesity trials had higher baseline blood pressures on average. The semaglutide dose in the STEP program (2.4 mg) was higher than the dose in SUSTAIN-6 (0.5 or 1.0 mg). And the weight loss was greater: STEP-1 participants lost a mean of 14.9% body weight versus 4.3% in SUSTAIN-6. Since weight loss drives the majority of the blood pressure effect, more weight loss produces more blood pressure reduction.
Why GLP-1 drugs lower blood pressure: the mechanism question
The Kennedy et al. mediation analysis produced a striking finding: weight loss accounted for approximately 89% of semaglutide's systolic blood pressure reduction.[1] That leaves roughly 11% attributed to weight-independent mechanisms. What are they?
Ribeiro-Silva et al. (2023) reviewed the mechanistic evidence and identified several pathways through which GLP-1 receptor activation may lower blood pressure independent of weight loss.[9]
Natriuresis. GLP-1 receptors are expressed in the renal proximal tubule. Activation promotes sodium excretion by inhibiting the sodium-hydrogen exchanger 3 (NHE3), which reduces plasma volume and consequently blood pressure. Animal studies have demonstrated this effect directly, and it appears to operate independently of weight changes.
Endothelial function. GLP-1 receptor activation increases nitric oxide production in endothelial cells, promoting vasodilation. Preclinical data show reduced endothelial dysfunction and improved flow-mediated dilation. A 2025 retrospective study by Sugiyama et al. found that once-weekly semaglutide improved vascular endothelial function in patients with type 2 diabetes.[10]
Vascular inflammation. GLP-1 agonists reduce circulating markers of inflammation (C-reactive protein, interleukin-6, TNF-alpha) and attenuate oxidative stress in arterial walls. Chronic vascular inflammation contributes to arterial stiffness, which elevates blood pressure. For a deeper look at the anti-inflammatory mechanisms of GLP-1 drugs, see our dedicated article.
Autonomic modulation. Some evidence suggests GLP-1 receptor agonists shift autonomic balance from sympathetic overactivation toward parasympathetic tone, which would lower blood pressure. This pathway is less well established in humans.
Ferdinand et al. (2023) attempted to separate weight-dependent from weight-independent effects using data from the REWIND trial (dulaglutide). The analysis found that while most of the blood pressure reduction tracked with weight loss, a small but statistically significant component persisted after adjusting for body weight changes.[11] The clinical significance of this weight-independent fraction is debated.
The heart rate paradox
GLP-1 agonists lower blood pressure but increase heart rate. Across the class, resting heart rate rises by 2 to 4 beats per minute.[2] This is a well-documented and consistent finding.
The mechanism is not fully resolved. Proposed explanations include direct activation of GLP-1 receptors in the sinoatrial node, compensatory sympathetic activation in response to vasodilation and natriuresis, and central nervous system effects. The increase is modest and has not translated into excess arrhythmia risk in the large cardiovascular outcome trials. The LEADER trial showed no increase in serious arrhythmias with liraglutide despite the heart rate increase.[6]
However, the heart rate increase partially offsets the hemodynamic benefit of blood pressure reduction. A lower blood pressure at a higher heart rate does not produce the same cardiovascular risk reduction as a lower blood pressure at a stable heart rate. This may partly explain why the blood pressure reductions observed with GLP-1 drugs, while real, do not translate into proportionally larger cardiovascular benefits than would be predicted from traditional antihypertensive agents.
GLP-1 agonists for resistant hypertension
Resistant hypertension, defined as blood pressure remaining above goal despite three or more antihypertensive agents including a diuretic, affects an estimated 10-15% of hypertensive patients. Jarade et al. (2024) reviewed the potential role of GLP-1-based therapies in this population.[12]
The rationale is straightforward. Many patients with resistant hypertension have obesity, and obesity contributes to hypertension through multiple pathways: increased sympathetic activity, sodium retention, renal compression from visceral fat, and elevated aldosterone levels. GLP-1 agonists address several of these pathways simultaneously through weight loss and the direct natriuretic and vascular effects described above.
Observational data suggests that patients with resistant hypertension who start GLP-1 agonists for diabetes or weight management often experience blood pressure reductions sufficient to reduce the number of antihypertensive medications they need. Kennedy et al. found that the anti-hypertensive treatment intensity score decreased for semaglutide-treated patients compared to placebo, meaning physicians were able to reduce blood pressure medication doses.[1]
No randomized trial has tested GLP-1 agonists specifically as add-on therapy for resistant hypertension as a primary endpoint. The existing evidence comes from post hoc analyses of trials designed for other purposes. The signal is consistent, but whether GLP-1 drugs will earn a hypertension indication remains speculative.
How GLP-1 blood pressure effects compare across drugs
The evidence is not uniform across the class. Wang et al. (2013) conducted an early meta-analysis comparing exenatide and liraglutide specifically, finding exenatide reduced SBP by 5.24 mmHg versus placebo and 3.46 mmHg versus insulin glargine, while liraglutide showed smaller reductions.[13] More recent data suggests semaglutide and tirzepatide produce larger blood pressure effects than earlier GLP-1 drugs, likely reflecting greater weight loss at higher doses.
Goud et al. (2016) reviewed the class-level evidence and noted that short-acting GLP-1 agonists (exenatide twice daily, lixisenatide) produced different hemodynamic profiles than long-acting agents (liraglutide, exenatide weekly, dulaglutide, semaglutide).[14] Short-acting agents tended to have more pronounced postprandial effects on blood pressure but smaller 24-hour ambulatory reductions. Long-acting agents produced more sustained, round-the-clock blood pressure lowering. This distinction parallels the cardiovascular outcome trial results, where long-acting agents showed greater MACE reductions.
| Drug | Trial/Analysis | SBP Reduction (mmHg) | Context |
|---|---|---|---|
| Semaglutide 2.4 mg | Kennedy 2024 IPD meta-analysis | -4.95 | Pooled RCTs |
| Semaglutide (subcut) | Ala 2025 meta-analysis | -3.71 | 20 trials, 33,000+ pts |
| Tirzepatide 15 mg | SURMOUNT-1 stratified | -7.4 | Obesity, no diabetes |
| Liraglutide | LEADER | -1.2 | T2D, high CV risk |
| Semaglutide 0.5/1.0 mg | SUSTAIN-6 | -2.6 | T2D, high CV risk |
| GLP-1 RA class | Wong 2025 meta-analysis | -3.37 | Overweight/obese |
| Exenatide | Wang 2013 meta-analysis | -5.24 | vs placebo |
The dose-response relationship is consistent: higher doses produce greater weight loss and greater blood pressure reduction. Whether the blood pressure effect will scale further with next-generation agents like CagriSema (semaglutide plus cagrilintide) remains to be determined.
What the evidence does not resolve
Several questions remain open despite the volume of data.
Ambulatory blood pressure monitoring (ABPM) data is limited. Most trials measured office blood pressure at scheduled visits. ABPM captures the full 24-hour profile, including nocturnal dipping, which is a stronger predictor of cardiovascular events than office readings. The few ABPM substudy results available suggest the reductions are real but may differ from office measurements.
Effect durability after weight stabilization is uncertain. If 89% of the blood pressure reduction comes from weight loss, what happens when weight plateaus at 6-12 months? Does the blood pressure benefit stabilize, diminish, or continue to accumulate? The trial follow-up periods do not cleanly separate the weight loss phase from the maintenance phase.
Impact on blood pressure variability is unstudied. Visit-to-visit blood pressure variability is an independent cardiovascular risk factor. Whether GLP-1 drugs reduce or increase blood pressure variability has not been systematically assessed.
Population-specific effects need clarification. The blood pressure reductions in existing trials come predominantly from populations with obesity, type 2 diabetes, or established cardiovascular disease. Whether lean individuals, younger populations, or patients with isolated hypertension (no obesity or diabetes) would see similar reductions is unknown.
The Bottom Line
GLP-1 receptor agonists consistently reduce systolic blood pressure by 2 to 5 mmHg across meta-analyses, with semaglutide and tirzepatide at higher doses producing larger reductions of 5 to 7 mmHg. Approximately 89% of the effect is mediated by weight loss, with natriuresis, endothelial function improvements, and anti-inflammatory effects contributing the remainder. The class also increases heart rate by 2 to 4 bpm, partially counteracting the hemodynamic benefit. The blood pressure reduction adds incrementally to existing antihypertensive therapy and contributes to the broader cardiovascular risk reduction demonstrated in the outcome trials, but GLP-1 agonists are not a substitute for dedicated antihypertensive treatment.